Synairgen PLC - ESG Rating & Company Profile powered by AI
The assessment of Synairgen PLC uses data from across the internet and also from available filings by Synairgen PLC. This webpage of Synairgen PLC was assembled by All Street Sevva using cutting edge AI. Alternative companies in the scoring peer group for Synairgen PLC are shown.
Synairgen PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 3.2 and governance score of 1.6.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Synairgen PLC | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Synairgen PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Synairgen PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Synairgen PLC report the average age of the workforce?
Sign up for free to unlockDoes Synairgen PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Synairgen PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Synairgen PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Synairgen PLC offer flexible work?
Sign up for free to unlockDoes Synairgen PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Synairgen PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Synairgen PLC conduct supply chain audits?
Sign up for free to unlockDoes Synairgen PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Synairgen PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Synairgen PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Synairgen PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Synairgen PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Synairgen PLC disclose water use targets?
Sign up for free to unlockDoes Synairgen PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Synairgen PLC have a product recall in the last two years?
Sign up for free to unlockDoes Synairgen PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Synairgen PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Synairgen PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Synairgen PLC disclose parental leave metrics?
Sign up for free to unlockDoes Synairgen PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Synairgen PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Synairgen PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Synairgen PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Synairgen PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Synairgen PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Synairgen PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Synairgen PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Synairgen PLC disclose its waste policy?
Sign up for free to unlockDoes Synairgen PLC report according to TCFD requirements?
Sign up for free to unlockDoes Synairgen PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Synairgen PLC disclose energy use targets?
Sign up for free to unlockDoes Synairgen PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Synairgen PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Synairgen PLC
These potential risks are based on the size, segment and geographies of the company.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.